i H E PRODUCTION of moderate or severe hypoglycemic reactions by means of insulin is a common procedure in the treatment of patients with psychoses. Ambulatory treatment in the home or office, employing smaller doses of insulin to produce milder reactions, has also been found of value in the handling of patients with, severe psychoneuroses ( i ) . Insulin therapy is limited to some extent in that it is contraindicated in patients with overt heart disease or those suspected of having coronary arterial disease. The release of epinephrine consequent to hypoglycemia may increase cardiac work to a dangerous degree or may give rise to myocardial damage in such individuals C 2 )-As a consequence of these facts, many persons whose mental status might be helped by insulin hypoglycemia are unable to undergo this treatment.
If agents were available which neutralized the potentially harmful effects of endogenous epinephrine on the circulatory system-the increases in blood pressure, heart rate, pulse pressure, and cardiac output-the safe use of insulin therapy in elderly or cardiac patients would be possible. The availability of socalled "adrenolytic" or "sympatholytic" drugs such as dibenamine (N, N-dibenzyl-/?-chloro- This research was supported by a grant from Smith, Kline and French Laboratories.
Received for publication March 8, 1951. ethylamine) or the newer SKF #501, a dibenamine congener (N-9-fluorenyl, N-ethyl-/?-chloroethylamine), suggested their use for this purpose. The effects of SKF #501 are qualitatively similar to those of dibenamine, but the former is approximately ten times as potent as the latter (3); accordingly SKF #501 was chosen for this study to determine whether blockade of adrenergic impulses produced by this agent could offer protection against the effects of excessive amounts of endogenous epinephrine.
Method
Hypoglycemia was induced in two normal volunteers by means of the intravenous injection of insulin, and measurements of heart rate, blood pressure, and blood sugar level were made at intervals. The subjects remained in the recumbent position throughout the period of observation. On the following day in each case the subject received 0.5 mg. per Kg. body weight of SKF #501 intravenously. This dose, comparable to 5 mg. per Kg. body weight of dibenamine in "adrenolytic" activity, produced adrenergic blockade sufficient to cause postural hypotension, miosis, and nasal congestion one-half to one hour after injection. Insulin was again given intravenously and measurements of heart rate, blood pressure, and blood sugar made as in the initial experiments. The hypoglycemia was terminated by the intravenous administration of solution of glucose.
PSYCHOSOMATIC MEDICINE
The amount of fall in hlood sugar level following injection of insulin was similar before and after SKF #501. Hypoglycemia in each instance was accompanied by the usual symptoms of drowsiness, weakness, hunger, and sweating. There was little change in the levels of systolic pressure during hypoglycemia with and without SKF #501, but a marked fall in diastolic pressure occurred during hypoglycemia induced after the injection of SKF #501 as compared with the more moderate fall after insulin alone ( Figs. 1 and 2) ; there was a greater increase in pulse pressure during hypoglycemia after SKF #501. The VOL. XIV, NO. 4, 1952 tachycardia which accompanied the hypoglycemic reaction appeared earlier and was much exaggerated under the influence of SKF #501 (Figs. 1 and 2) ; discomfort owing to awareness of heart action and anxiety also were more pronounced.
Discussion
Comparison of the cardiovascular effects of hypoglycemia before and after the adminis- tration of SKF #501 showed that this dibenamine analogue did not prevent tachycardia or increased pulse pressure. Judging from the increase in the latter the effect of this "adrenolytic" agent in hypoglycemia was to cause greater stroke volume as well as increased pulse rate, and hence a greater cardiac output than in insulin hypoglycemia alone. It should be noted that the cardiovascular responses which occur during hypoglycemia are those usually associated with Z-epinephrine and not nor-epinephrine (4); under the influence of adrenergic blockade sufficient to cause postural hypotension, the cardiovascular changes in hypoglycemia exemplify certain effects of Z-epinephrine in an exaggerated manner. The findings described here are in accord with data already in the literature (5); while dibenamine is known to prevent the arrhythmias and rise in blood pressure caused by epinephrine (8), neither dibenamine (8) nor SKF #501 prevents the cardio-accelerator effect of epinephrine; the positive inotropic effect of epinephrine on cardiac muscle is likewise not prevented by dibenamine (8). In addition, neither dibenamine, in doses of 5 mg. per Kg. (5, 8) nor SKF #501 in doses of 0.5 mg. per Kg. (7) in man, prevents the rise in blood sugar caused by epinephrine in the manner accomplished by sympathectomy (9); in toxic doses of 2 mg. per Kg. in rabbits, SKF #501 may prevent hyperglycemia caused by epinephrine (9) but this is above a safe level for use in man. These phenomena indicate the inaccuracy of the concept that regards these drugs as truly adrenolytic or sympatholytic.
Neither dibenamine nor SKF #5 01 ' s u s e ' ful in preventing the cardiovascular strains associated with hypoglycemia following the injection of insulin; in the dosages used in man the constrictor effect of epinephrine on the peripheral vessels is inhibited but the action of epinephrine in increasing the work of the heart is not prevented.
N-9-fluoren yl, N-ethy l-/3-chloroethyl amine, a dibenamine congener, does not prevent the adverse effects of insulin-induced hypoglycemia on the heart. Under its influence the increases in heart rate and pulse pressure in hypoglycemia are greater than in hypoglycemia alone; feelings of severe anxiety were experienced by normal subjects made hypoglycemic while under the influence of this "adrenolytic" agent. 
